TRIV-509 / Triveni Bio - LARVOL DELTA

TRIV-509, a dual inhibitor of KLK5 and KLK7, rapidly improves barrier integrity and markers of epidermal differentiation in atopic dermatitis skin explants (SID 2025) - "Finally, TRIV-509 significantly increased the number of DSG1+ cells in the appropriate layers of the epidermis. Together this data demonstrates that KLK5 and KLK7 inhibition rapidly improves the barrier integrity and markers of epidermal differentiation ex vivo, thereby highlighting the therapeutic potential of TRIV-509 in AD."

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus • DSC1 • KLK5 • KLK7

Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis (PRNewswire) - "Triveni Bio, Inc...announced the initiation of dosing in healthy volunteers for its first-in-human Phase 1 clinical trial of TRIV-509. This study will assess the safety and tolerability of TRIV-509 and is the first of three clinical trials the company expects to begin in 2025 as Triveni advances its anti-kallikrein mechanism into patients with moderate-to-severe atopic dermatitis (AD)."

New trial • Trial status • Atopic Dermatitis

KLK5/7 targeting antibody, TRIV-509, ameliorates barrier dysfunction, inflammation and itch in atopic dermatitis models. (SID 2024) - No abstract available

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • KLK5